Chromosomal rearrangements are a recently recognized genetic alteration in solid tumors including in non- small cell lung cancer (NSCLC). Rearrangements in ALK, ROS1 and RET, all of which lead to oncogenic fusion proteins, have been reported and evaluation of whether kinase inhibitors will be effect therapies for NSCLC patient harboring these genetic alterations is underway.. ALK is a validated therapeutic target based on the results of a phase III clinical trial demonstraing improved progression free survival (PFS) for ALK rearranged NSCLC patients receiving treatment with the ALK inhibitor crizotinib compared with chemotherapy. Encouraging early signs of clinical activity has also been observed for crizotinib in ROS1 rearranged NSCLC. Clinical activity of crizotinib has also been observed in ALK rearranged lymphomas and pediatric neuroblastomas. Despite the clinical efficacy of crizotinib in ALK and ROS1 rearranged NSCLC, all patients will ultimately develop acquired drug resistance. For ALK NSCLC patients,PFS is relatively short (7-8 months) suggesting that understanding the mechanisms of acquired drug resistance and developing alternative treatment strategies are urgently needed. To date, mechanisms of resistance to ALK inhibitors include secondary mutations in ALK and activation of bypass signaling pathways (mediated by EGFR or KIT). These observations have led to the preclinical and clinical development of second generation ALK inhibitors, including by us, as well therapies combining EGFR and ALK inhibitors. The understanding of the mechanisms of resistance, and strategies to overcome them, are just beginning to be understood for ALK rearranged NSCLC. For ROS1, they have not yet been described but are fully expected to occur. The co-principle investigators of this proposal have previously identified mechanisms of resistance to kinase inhibitors (including ALK targeted therapies), have developed novel non-covalent and covalent kinase inhibitors against drug resistant forms, and conducted translational and clinical studies of kinase inhibitors in NSCLC. Here we propose to integrate genomic studies of crizotinib resistant cancers from ALK and ROS1 rearranged NSCLC patients treated with crizotinib along with preclinical models of crizotinib resistance, coupled with the development of the first covalent dual ALK/ROS1 inhibitors as well as rationale combination therapies aimed at overcoming crizotinib resistance. Our findings will have direct and immediate translational relevance for ALK and ROS1 rearranged NSCLC patients. We plan to achieve these goals through the following specific aims:
Aim 1 : To discover and validate mechanisms of resistance to ALK targeted therapies~ Aim 2: To predict and validate drug resistance mechanism to ROS1 targeted therapies~ Aim 3: To develop the first potent and selective dual inhibitors of ALK and ROS1 with pharmacological properties suitable for testing in preclinical in vitro and in vivo models.
Lung cancer patients whose tumors harbor chromosomal rearrangements in ALK or ROS1 can be effectively treated with kinase inhibitors including crizotinib. All patients ultimately develop acquired drug resistance and new therapies are urgently needed. The studies in this proposal will evaluate drug resistance mechanisms directly from lung cancer patients treated with ALK or ROS1 inhibitors and develop new therapeutic strategies, including covalent ALK/ROS1 inhibitors, to treat patients with ALK or ROS1 rearrangements.
| Powell, Chelsea E; Gao, Yang; Tan, Li et al. (2018) Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). J Med Chem 61:4249-4255 |
| Hatcher, John M; Wu, Guowei; Zeng, Chuyue et al. (2018) SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell Chem Biol 25:460-470.e6 |
| Jang, Jaebong; Son, Jung Beom; To, Ciric et al. (2017) Discovery of a potent dual ALK and EGFR T790M inhibitor. Eur J Med Chem 136:497-510 |
| Chong, Curtis R; Bahcall, Magda; Capelletti, Marzia et al. (2017) Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res 23:204-213 |
| Wilson, Frederick H; Johannessen, Cory M; Piccioni, Federica et al. (2015) A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 27:397-408 |
| Hatcher, John M; Bahcall, Magda; Choi, Hwan Geun et al. (2015) Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. J Med Chem 58:9296-9308 |
| Voena, Claudia; Menotti, Matteo; Mastini, Cristina et al. (2015) Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res 3:1333-1343 |
| Gao, Xin; Sholl, Lynette M; Nishino, Mizuki et al. (2015) Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol 10:1648-52 |
| Chen, Zhao; Akbay, Esra; Mikse, Oliver et al. (2014) Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. Clin Cancer Res 20:1204-1211 |
| de Figueiredo-Pontes, Lorena Lobo; Wong, Daisy Wing-Sze; Tin, Vicky Pui-Chi et al. (2014) Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol 9:248-53 |
Showing the most recent 10 out of 25 publications
